Could a tiny dose of LSD ease PMS? new study investigates
NCT ID NCT07189299
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests whether very low doses of LSD (10 micrograms) taken daily or every other day during the premenstrual phase can reduce symptoms of severe PMS or PMDD. 150 women will be randomly assigned to LSD or placebo for three menstrual cycles. The goal is to see if LSD can safely ease mood and physical symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LSD (lysergic acid diethylamide)
What this could lead to
If it works, this could point toward a new way to manage severe PMS or PMDD symptoms using low-dose LSD during the premenstrual phase.
What could go wrong
This is an early-phase study with a small dose and short treatment window. LSD is a controlled substance, and side effects or lack of benefit are possible. Results may not apply to everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Pharmacology & Toxicology, University Hospital Basel
Basel, Canton of Basel-City, 4056, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••